ReleaseWire Connect

GBI Research’s report, “Dental Device Market to 2017 – CAD/CAM and Minimal Invasive Cosmetic Dentistry to Drive the Market” provides key data, information and analysis on the global dental devices market. The report provides the market landscape, competitive landscape and market trend information on seven dental devices market categories: CAD/CAM dental systems, crowns and bridges, dental biomaterials, dental chairs and equipment, dental lasers, dental implants and dental radiology equipment.

GBI Research, the leading business intelligence provider, has released its latest research, “Emerging Cancer Vaccines Market to 2017 – Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market”, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

GBI Research, the leading business intelligence provider, has released its latest research “Endpoints- Clinical Trials in Central nervous system Disorders” which provides an insight into different endpoints that are used in central nervous system clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed Central nervous system drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising Central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

ReportsnReports.com adds Biopharm Reports Publishers Market Research Report “VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011’’ to its store.

As the off-trade has emerged as the primary channel of engagement between brand and consumers, the on-trade’s role in brand building and in sales generation has had to change. On-trade exclusives; targeting under-represented on-trade demographic groups; harnessing the power of social media; and making the on-trade experience both interactive and experiential will be vital going forward.

Despite a number of well-established therapies, the asthma and COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented at this year’s respiratory conferences. Numerous product launches are expected in the next 10 years, which will fragment the markets, although a handful of companies will maintain market dominance.

ReportsnReports – Product Profiles: Depression – Next generation vies for second-line patients – Depression treatment market

This report firstly introduces Low-E Glass (Include Offline Online LOW-E GLASS) with its definition, classification, industry chain & other related information. It covers Low-E Glass manufacturing technology analysis, summary statistics of China’s 26 manufacturers, 2009-2015 Low-E Glass capacity production, supply, demand, shortage and Low-E Glass selling price, cost, profit margin and production value. It also covers offline online Low-E Glass production market share, and different thickness (4-12mm) production market share, Offline(Single Silver Double Silver Triple Silver) production market share and China supply demand shortage etc information.

ReportsnReports.com adds NanoMarkets LC Market Research Report “Molybdenum Markets in the Electronics and Solar Industries -2011’’ to its store.

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status. The evolution of a fragmented oncology market will decrease the value of the top 20 branded therapies by $8.6 billion between 2010 and 2020.